Jamaal L James1,2, Justin M Balko1,3,4,2. 1. Department of Medicine, Vanderbilt University Medical Center, Nashville TN. 2. Department of Cancer Biology Program, Vanderbilt University Medical Center, Nashville TN. 3. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville TN. 4. Department of Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville TN.
Abstract
PURPOSE OF REVIEW: Immune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB, and anti-PD-L1 therapy is now approved in PD-L1+ metastatic TNBC, in combination with chemotherapy. RECENT FINDINGS: Nearly 40% of PD-L1+ TNBC patients did not respond to this combination. Thus, additional biomarkers appear to be necessary to more precisely identify potential responders. A comprehensive analysis of the breast tumor microenvironment (TME) and peripheral blood may identify potential biomarkers for a more accurate selection of patients likely to respond to ICB. SUMMARY: Herein, we summarize key features of the breast TME, and beyond, that may hold predictive power in determining immunotherapy benefit. Incorporation of these features in controlled clinical trials may help further guide personalized care for BC immunotherapy.
PURPOSE OF REVIEW: Immune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB, and anti-PD-L1 therapy is now approved in PD-L1+ metastatic TNBC, in combination with chemotherapy. RECENT FINDINGS: Nearly 40% of PD-L1+ TNBC patients did not respond to this combination. Thus, additional biomarkers appear to be necessary to more precisely identify potential responders. A comprehensive analysis of the breast tumor microenvironment (TME) and peripheral blood may identify potential biomarkers for a more accurate selection of patients likely to respond to ICB. SUMMARY: Herein, we summarize key features of the breast TME, and beyond, that may hold predictive power in determining immunotherapy benefit. Incorporation of these features in controlled clinical trials may help further guide personalized care for BC immunotherapy.
Entities:
Keywords:
Breast cancer; biomarkers; programmed death-ligand 1
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: Jules Gadiot; Anna I Hooijkaas; Andrew D M Kaiser; Harm van Tinteren; Hester van Boven; Christian Blank Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: Elisa Rosati; C Marie Dowds; Evaggelia Liaskou; Eva Kristine Klemsdal Henriksen; Tom H Karlsen; Andre Franke Journal: BMC Biotechnol Date: 2017-07-10 Impact factor: 2.563
Authors: Ailed Cruz-Collazo; Jean F Ruiz-Calderon; Hector Picon; Luis D Borrero-Garcia; Irmaris Lopez; Linette Castillo-Pichardo; Maria Del Mar Maldonado; Jorge Duconge; Julia I Medina; Marvin J Bayro; Eliud Hernández-O'Farrill; Cornelis P Vlaar; Suranganie Dharmawardhane Journal: Mol Cancer Ther Date: 2021-10-04 Impact factor: 6.009